March 22-24, 2024 – Lake Louise, Alberta
WELCOME TO CCOLD 2024
Please join us for the 14th Annual Canadian Conference on Lymphoproliferative Disorders (CCOLD) taking place as a hybrid conference in Lake Louise, Alberta on March 22 to 24, 2024.
CCOLD provides a unique opportunity for attendees to interact with international experts in the field of hematologic malignancies. The scope of this meeting will highlight both recent research findings elucidating the pathophysiology of these diverse diseases, as well as changes in therapeutic advances that have had a large impact in the management of our patients. As in previous meetings the format will be didactic presentations as well as case based panel discussions. There will be opportunity for audience participation via keypad polling devices with the entire faculty featured during the panel discussions.
Internationally known researchers in Lymphoproliferative Disorders will provide keynote lectures and their perspectives on optimal management.
We will continue to support the “Young Investigators Research Awards Program” which has been very successful in providing educational and research support to trainees interested in Lymphoproliferative Disorders. Posters outlining their research will be focused at a special reception Saturday afternoon.
We look forward to seeing you at this educational event!
Dr. Wendy Lam, Burnaby, BC
Dr. Laurie Sehn, Vancouver, BC
On behalf of the CCOLD Planning Committee
Dr. Anca Prica, Toronto, ON
Dr. Pamela Skrabek, Winnipeg, MB
Dr. Carolyn Owen, Calgary, AB
Dr. Darrell White, Halifax, NS
Dr. Nathalie Johnson, Montreal, QC
Dr. Irwindeep Sandhu, Edmonton, AB
Dr. Julie Stakiw, Saskatoon, SK
This meeting has been designed to meet the educational needs of hematologists, oncologists, general practitioners in oncology and other health care providers involved in the management of patients with lymphoproliferative and plasma cell disorders.
Highlighting both recent research findings elucidating the pathophysiology of these diverse diseases, as well as changes in therapeutic advances that have had a large impact in the management of our patients.